CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
RBT-9drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04072861
NCT04072861Phase 1Completed
CompareCT.gov

A Phase 1b Dose-escalating Study With RBT-9 in Healthy Volunteers and Volunteers With Chronic Kidney Disease Stage 3/4

Renibus Therapeutics, Inc.·interventional·Posted Aug 28, 2019·Updated Jan 6, 2025

In Brief

A Phase 1 clinical trial evaluating RBT-9 for Healthy Volunteers and Chronic Kidney Disease. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-9 in healthy volunteers and in subjects with Stage 3/4 CKD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Chronic Kidney Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 28, 2019
Enrollment StartMar 31, 2019
Primary CompletionJul 31, 2020
Study CompletionOct 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.8 years ago

Interventions

RBT-9drug

intravenous administration